Device Trial Radar · NCT05334758
Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test
Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
282
Actual
Start
May 12, 2022
Primary completion
Jul 25, 2022
Study completion Jul 25, 2022
Sponsor
- Lead sponsor
- BioTeke USA, LLCNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- CSSi Life Sciences
- First posted
- Apr 19, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years, up to 94 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the performance of the Bio-Self COVID-19 Antigen Home Test. The study will evaluate the accuracy (sensitivity and specificity) in a simulated home use environment when compared to a high-sensitivity Emergency Use Authorization (EUA) SARS-CoV-2 RT-PCR assay.
Conditions
- COVID-19
Interventions
Bio-Self COVID-19 Antigen Home TestDevice
At home COVID-19 antigen test kit
Standard of Care COVID-19 TestDevice
Standard of care
RT-PCR TestDiagnostic test
High Sensitivity RT-PCR COVID-19 Test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive Percent Agreement - SensitivityTime frame: 48 hours
- Negative Percent Agreement - SpecificityTime frame: 48 hours
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
L&A Morales Healthcare, Inc.
Miami, Florida
CDR Health
Tallahassee, Florida
Centennial Medical
Elkridge, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.